key: cord-0874386-ub17oj7f
authors: Morris, C Paul; Luo, Chun Huai; Amadi, Adannaya; Schwartz, Matthew; Gallagher, Nicholas; Ray, Stuart C; Pekosz, Andrew; Mostafa, Heba H
title: An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern
date: 2021-07-17
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab636
sha: f2e21039e3d3639790fe76e87583b0ddb211a8d9
doc_id: 874386
cord_uid: ub17oj7f

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants concerning for enhanced transmission, evasion of immune responses, or associated with severe disease have motivated the global increase in genomic surveillance. In the current study, large-scale whole-genome sequencing was performed between November 2020 and the end of March 2021 to provide a phylodynamic analysis of circulating variants over time. In addition, we compared the viral genomic features of March 2020 and March 2021. METHODS: A total of 1600 complete SARS-CoV-2 genomes were analyzed. Genomic analysis was associated with laboratory diagnostic volumes and positivity rates, in addition to an analysis of the association of selected variants of concern/variants of interest with disease severity and outcomes. Our real-time surveillance features a cohort of specimens from patients who tested positive for SARS-CoV-2 after completion of vaccination. RESULTS: Our data showed genomic diversity over time that was not limited to the spike sequence. A significant increase in the B.1.1.7 lineage (alpha variant) in March 2021 as well as a transient circulation of regional variants that carried both the concerning S: E484K and S: P681H substitutions were noted. Lineage B.1.243 was significantly associated with intensive care unit admission and mortality. Genomes recovered from fully vaccinated individuals represented the predominant lineages circulating at specimen collection time, and people with those infections recovered with no hospitalizations. CONCLUSIONS: Our results emphasize the importance of genomic surveillance coupled with laboratory, clinical, and metadata analysis for a better understanding of the dynamics of viral spread and evolution.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly evolving pandemic and within a little over 1 year, >162 million cases were globally confirmed, with >3 million deaths worldwide (https://coronavirus.jhu.edu/map.html). Since its first introduction, genomic sequencing revealed global diversity and identified variations in different regions of SARS-CoV-2 genomes [1] [2] [3] [4] [5] . The aspartate-to-glycine change at position 614 (S: D614G) substitution in the spike (S) protein garnered much attention in mid-2020 and rapidly became globally predominant [2, 6, 7] . Most recently, variants with higher transmissibility are raising a major concern (variants of concern [VOCs]). Lineage B.1.1.7 (alpha variant), characterized by an unusual large number of changes in its genome [8] and first detected in the United Kingdom in September 2020, is globally circulating [9] [10] [11] [12] . Along with multiple mutations in the spike protein, there are 3 specific changes of particular concern: the S: N501Y, shown to enhance the binding affinity to angiotensin-converting enzyme 2 (ACE2), the S: 69-70del that could potentially cause immune escape, and the S: P681H that is close to the furin cleavage site [8, 13, 14] . Other S: N501Y emerging VOCs include B.1.351 (beta) and P.1 (gamma), which both carry S: E484K and became predominant in their countries of origin [15, 16] .

In addition, regional variants of interest (VOIs) and VOCs evolved in the United States and showed marked spread and concerning genomic changes. California variants were associated with a spike in the number of cases and were reported from other regions in the United States [17] . These variants are characterized by the S: L452R, which could affect neutralization by monoclonal antibodies [18, 19] . A large percentage of screened isolates in New York City belonged to VOI (B.1.526 [iota] and B.1.525 [eta] ) [20] . The significance of the evolution of regional variants and VOCs has become an area of international focus.

We previously reported the genomic diversity of SARS-CoV-2 at its early introduction in March 2020 to the National Capital Region [3] . In this report, we provide an update on the diversification of SARS-CoV-2 after 1 year of the pandemic.

Research was conducted under protocol IRB00221396 with a waiver of consent. Whole genomes were deposited at GISAID (Global Initiative on Sharing All Influenza Data) (Supplementary Table 1 ). Whole-genome data were made available publicly, and raw genomic data requests may be directed to the correspondence author (H. H. M.)

Remnant nasopharyngeal or lateral midturbinate nasal clinical specimens that tested positive for SARS-CoV-2 after standard of care diagnostic or screening assays were performed across the Johns Hopkins Medical System (representing a wide geographic area in the National Capital Region-Maryland, Washington, DC, and Virginia). Different molecular assays are used for SARS-CoV-2 detection, including the NeuMoDx (Qiagen) [21, 22] , cobas (Roche) [21] , Aptima (Hologic), Xpert Xpress SARS-CoV-2/Flu/RSV (Cepheid) [23] , ePlex respiratory pathogen panel 2 (GenMark) [24] , Accula, and RealStar SARS-CoV-2 assays (altona Diagnostics) [25] . Testing was performed in accordance with the manufacturer instructions and our in house validated protocols. Specimen selection was random except for cycle threshold (Ct), where values <20 were preferentially selected when available.

Automated nucleic acid extraction was performed using the chemagic 360 instrument (PerkinElmer), following the manufacturer's protocol. Libraries were prepared using the ARTIC protocol, as described elsewhere [3] Nanopore reads were base-called with MinKNOW and demultiplexed with Guppy v3.5.2 barcoder software, requiring barcodes at both ends. Reads were size restricted, and alignment and variant calling were performed with the artic-ncov2019 medaka protocol. Thresholds were set to a minimum of 90% coverage and 100 mean depth. Mutations were visually confirmed with the Integrated Genomics viewer (version 2.8.10). Clades were determined using Nextclade beta version 0.12.0 (clades.nextstrain. org) [26] , and lineages were determined with the Pangolin coronavirus disease 2019 (COVID-19) lineage assigner (COG-UK; cog-uk.io).

Clinical data were retrieved from the electronic medical records manually. Severity index scores were assigned as follows: 0 indicated asymptomatic, 1, outpatient or admitted for another reason without oxygen requirement; 2, inpatient (or oxygen requirement for COVID-19); 3, intensive care unit (ICU) admission; and 4, death. Severity scores were determined at the time of clinical data analysis, which was >30 days after the date of sample collection in all patients.

Fisher exact, χ 2 , and Kruskal-Wallis tests were performed to show associations with Bonferroni correction, depending on the type and number of results evaluated. Post hoc analysis was performed using Conover analysis with Holmes adjustment or χ 2 analysis. Odds ratios were calculated with MedCalc's odds ratio calculator, using a method described elsewhere [27] .

A total of 378 107 tests were performed as of 1 April 2021, with 23 947 positive results identified. The positivity rates showed 2 distinctive peaks, in April 2020 and December 2020 to January 2021, with maximum 15-day rolling averages of 20.1% and 10.0%, respectively ( Figure 1A ). The end of January witnessed a reduction in the positivity that plateaued at a 15-day rolling average of 3.1% ( Figure 1A ).

A total of 1600 complete or near-complete genomes were obtained from samples collected between 26 October 2020 and 31 March 2021, constituting 14.3% of positive results during this time frame. Initially, clade 20A predominated, until December 2020 when 20G became the dominant clade ( Figure 1B ). This was associated with a peak in December and January ( Figure  1C ). The decline in 20G in February and March coincided with decreased positivity rates, and as clade 20I/501Y.V1 started to increase in frequency, positivity rates increased, proportions of positive samples from black patients increased, and the mean age of patients dropped (Figure 2A and 2B). The mean age for black patients was significantly lower than that of white patients (43.6 vs 50.1 years, respectively; t test, P < .001) ( Figure 2C and 2D). The mean Ct values were comparable in different race populations, with consistently lower Ct values in symptomatic versus asymptomatic patients (as determined by the ordering test codes that differentiate symptomatic from asymptomatic patients at the time of sample collection, Figure 2E and 2F), and 82%-85% of patients were symptomatic.

A high degree of diversity was noted from November 2020 until the end of March 2021 ( Figure 3 and Supplementary Table 2 Table 2 [20] .

Genomes from March 2021 were compared with those from March 2020 [3] . Of the 20 lineages circulating in this area in March 2020, only 3 (B.1, B.1.1, and B.1.1.207) were seen but rarely during March 2021 ( Figure 5A ). Twenty-eight lineages were present in March 2021 compared with 20 in March 2020. Diversity increased in NSP3, NS3 and the spike protein, but was similar in NSP12 and NSP14 in the 2 time frames ( Figure 5B 

The first VOC detected in our cohort was B. Table 1 Figure 2) .

We performed detailed record reviews in 116 patients (≥30 days after the date of sample collection) with hospital admissions in our cohort associated with the characterized samples. Sixteen patients were asymptomatic, and 87 were admitted for COVID-19. Eleven were admitted to the ICU with no associated deaths, and another 8 died. As expected, infections associated with hospitalization were caused by the more prevalent lineages ( Figure  6A ). However, B.1.243 was associated with noticeably high levels of ICU admissions or death, given its prevalence (Fisher exact test with Bonferroni correction P = .04; accounting for the total number of samples from each lineage) ( Figure 6A ; for lineage prevalence, refer to Figure 4B and Supplementary Table 2 ). Amino acid changes in hospitalized patients compared with all patients with ≥10% prevalence and a 5% change between the 2 groups showed that 4 mutations (S: P681H, NSP6: 106-108del, N: S194L, and N: T205I) were present to a higher degree, but not significantly higher or didn't reach statistical significance. Record reviews on all B.1.243-infected patients (122 patients) compared with all B.1.2-infected patients (as a control group; 395 patients) showed that the odds ratio for ICU admission or death associated with B.1.243 compared with B.1.2 infection was 4.9 (95% confidence interval, 1.4-17.9; P = .02) (Supplementary Figure 3) . Notably, this analysis did not adjust for patients' metadata or underlying conditions.

Thirty-six positive samples were collected between January and April from patients who tested positive after completing 2 doses of the COVID-19 Pfizer or Moderna vaccine. Only 14 of these had complete or near-complete genomes, with most genomes belonging to the B.1.1.7 variant ( Table 2 ). The Ct values from the clinical assays of positive samples after full vaccination ranged from 14.4 to 37.9 (23 samples with available Ct values), and low Ct values were correlated with higher depth and coverage of genome sequencing. More than half were in symptomatic patients, but all patients experienced only mild disease, which did not require hospitalization ( Table 2) .

Whole-genome sequencing for surveillance has been critical for monitoring the evolution of SARS-CoV-2 [3] . Our data showed an increase in the diversity of the spike protein and other genomic regions that include the NSP3 and NS3 over time. A shift from 20C clade in March 2020 to 20G by the end of the year and then to 20I/50Y.V1 in March 2021 was evident. The most common amino acid substitutions were extra-spike and included stable changes (eg, NS3:Q57H) and changes that increased (multiple NSP3 and NS8 changes). The spike amino acid changes that were most common after S: D614G included N501Y and P681H, with a notable increase in diversity compared with March 2020. A marked increase in B.1.1.7 started in February 2021. A regional variant was detected with increased prevalence in February 2021 that combined S: P681H and S: E484K. Notably, the circulation of variants carrying S: E484K has been temporary and the prevalence of this change remains sparse. On the other hand, a global increase in S: P681H is notable as a part of B.1.1.7.

Among the most frequently detected polymorphisms were the NSP6 deletions 106-108 that were present at a higher prevalence in hospitalized patients' genomes. NSP6 was shown to have a role in autophagosome generation [28] and these 3 amino acids are in a loop predicted to be external to the autophagy vesicles [28] . NSP6 was also shown to antagonize type I interferon and hence has a role in the evasion of the innate immune responses [29] . NSP3 showed the most increased diversity in March 2021, compared with March 2020. This protein is the largest protein encoded by coronaviruses, has multiple domains and functions, and is essential for viral replication [30] .

The evolution of VOCs was associated with a displacement of previous lineages. B.1.1.7 has become predominant by the end of March 2021. It is interesting that this variant was more successful than B.1.351, as both were circulating at the end . The genomic determinants of the success of certain variants in specific geographic locations or specific demographic groups remain an enigma, and factors that include previous natural infections, vaccination status, and vaccine efficacy for a geographic location likely affect these associations [32, 33] . Specifically, the association of lineage B.1.1.7 with younger age may be the result of preferential vaccination of older individuals before the emergence of this lineage in our geographic region. The relationship between viral genomic polymorphism and the change in disease severity has been an area of debate. Earlier research proposed an association of the S:D614G with mortality [34] ; however, this might be difficult to interpret owing to this substitution's early global dominance [35] . The evolution of VOCs emphasizes a natural selection in favor of these variants. Early studies concluded that there was no association between the B.1.1.7 and enhanced severity [36] , but other studies proposed a correlation with higher mortality [37] and hospitalization [38] rates. Signature mutations in the B.1.1.7, P1 and B.1.351 variants, including S: N501Y, could affect binding to ACE2 [39, 40] . Polymorphisms in ACE2 were shown to affect the COVID-19 outcome [41] ; hence, variants that affect ACE2 binding might have an effect on disease severity [42] .

Interestingly, we noticed a significant association of B.1.243 with ICU admission and mortality rate. This lineage shows amino acid substitutions NSP12:P323L, N:S194L,S:D614G, and S:P681H in >90% of specimens. It was also the only lineage with the occasional co-occurrence of N:T205I and N:S194L, which were both seen in higher percentages of sequences from known hospitalized patients. B.1.243 has substitution NSP3:G1300D, which was present in the genomes of all of the hospitalized patients, but in only about 80% of the total genomes of this lineage. Ongoing work by our group using cell culture and hamster models aims at examining the direct association of lineage B.1.243 with an increase in viral fitness or pathogenesis in wellcontrolled experiments. In addition, large-scale retrospective whole-genome sequencing between April 2020 and November 2020 is currently in progress to validate our observations.

With the nationwide increase in vaccination, the correlation between certain variants and breakthrough infections is an area of investigation. As of 26 April 2021, the Centers for Disease Control and Prevention reported 9245 positive cases after full vaccination, of a total of >95 million vaccinated individuals in the United States. Whether VOCs are more associated with infection after vaccination or escape of vaccine-induced immune responses will be challenging to investigate, owing to the relative infrequency of breakthrough cases and the increased prevalence of VOCs. A study from Israel proposed that vaccine breakthrough cases are more frequent with B.1.1.7 and B.1.351 [32] . Our data showed that among the 36 cases only 14 complete genomes were recovered, which was tightly correlated with the viral load in the respiratory specimens. The lineages detected represented the commonly circulating lineages in the time frame of specimen collection ( Table 2 ).

In conclusion, it is essential to characterize SARS-CoV-2 evolving variants in real time. We have implemented a surveillance protocol that allows us to identify predominant and novel variants. The limitations of our study include the relatively small number of patients with severe disease, which limited the adjustment of lineage associations with disease outcome to patients' metadata and underlying conditions and limited the restricted analysis to genomes of good quality, which might be tightly associated with viral loads at the time of sample collection.

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

The establishment of reference sequence for SARS-CoV-2 and variation analysis

The global population of SARS-CoV-2 is composed of six major subtypes

Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan area

Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread

Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: a computational biology approach

Structural consequences of variation in SARS-CoV-2 B.1.1.7

SARS-CoV-2 vaccines and the growing threat of viral variants

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: an early datadriven analysis

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Emergence of a novel SARS-CoV-2 variant in Southern California

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv

SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape

Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays

Multicenter evaluation of the NeuMoDx™ SARS-CoV-2 Test

Multi-center evaluation of the cepheid Xpert(R) Xpress SARS-CoV-2/Flu/RSV test

Clinical performance of the GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract infections

Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays

Nextstrain: real-time tracking of pathogen evolution

Handbook of parametric and nonparametric statistical procedures

Evolutionary analysis of SARS-CoV-2: how mutation of non-structural protein 6 (NSP6) could affect viral autophagy

Evasion of type I interferon by SARS-CoV-2

Nsp3 of coronaviruses: structures and functions of a large multi-domain protein

Linked clusters of SARS-CoV-2 variant B.1.351-Maryland

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv

Vaccine breakthrough infections with SARS-CoV-2 variants

SARS-CoV-2 genomic variations associated with mortality rate of COVID-19

Genetic variants of SARS-CoV-2-what do they mean?

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in communitytested cases of SARS-CoV-2 lineage B.1.1.7

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a wholegenome sequencing and hospital-based cohort study

The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant

Fast prediction of binding affinities of the SARS-CoV-2 spike protein mutant N501Y (UK variant) with ACE2 and miniprotein drug candidates

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Host polymorphisms may impact SARS-CoV-2 infectivity

from BioRad; receiving NIH grants for human papillomavirus research (grants 4UH3CA211396-03 and R01 CA243393); receiving consulting fees from Hologic, AlphaSight, and Guidepoint; and receiving honoraria/payments from Qiagen and GenMark for speaking, manuscript writing, or educational events, all outside the submitted work. All other authors report